Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Lipella Pharmaceuticals Inc. (LIPO) had Normalized Pre-Tax Income of $-1.25M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-1.25M |
|
-- |
|
-- |
|
$1.27M |
|
$-1.27M |
|
$0.02M |
|
$-1.25M |
|
|
Normalized Pre-Tax Income |
$-1.25M |
$-1.25M |
|
$-1.25M |
|
$-1.25M |
|
$-1.25M |
|
$-1.27M |
|
$-1.27M |
|
4.55M |
|
4.55M |
|
$-0.28 |
|
$-0.28 |
|
| Balance Sheet Financials | |
$2.08M |
|
$0.01M |
|
$0.27M |
|
$2.35M |
|
$0.64M |
|
-- |
|
$0.22M |
|
$0.86M |
|
$1.49M |
|
$1.49M |
|
$1.49M |
|
4.62M |
|
| Cash Flow Statement Financials | |
$-3.79M |
|
-- |
|
$3.46M |
|
$2.18M |
|
$1.86M |
|
$-0.33M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.24 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.79M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-84.30% |
|
-84.30% |
|
-53.37% |
|
-84.30% |
|
$0.32 |
|
$-0.83 |
|
$-0.83 |
|